Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. High Dividend Index (AUHD20)
3/23/2026, 12:00:00 AM
Announced positive topline results from the Phase 3 trial of its Lyme disease vaccine candidate (PF-07307405), showing over 70% efficacy. Estimated price impact ≥1% due to clinical success expected.
Korean Translation
라임병 백신 후보물질(PF-07307405)의 3상 임상시험에서 70% 이상의 효능을 보인 긍정적인 탑라인 결과를 발표함. 임상 성공에 따른 1% 이상의 주가 영향이 예상됨.
Related Recent Events
Murphy Oil Corp (MUR) · Earnings Release
The company is expected to release its Q1 2026 earnings results on or around May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Reynolds Consumer Products Inc (REYN) · Earnings Release
Quarterly earnings releases typically drive moderate price movements of at least 5%. Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.24 forecasted.
4/29/2026, 12:00:00 AM
First Hawaiian Inc (FHB) · Earnings Release
First Hawaiian, Inc. is scheduled to release its Q1 2026 financial results on April 22, 2026, with analysts forecasting an EPS of $0.53, expected. Market reaction is estimated at Medium importance as earnings reports typically drive price movement of 5% or more.
4/22/2026, 12:00:00 AM
CVB Financial Corp (CVBF) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS of $0.38 estimated. As quarterly earnings typically result in moderate price adjustments, low impact is expected.
4/22/2026, 12:00:00 AM
Peoples Bancorp Inc (PEBO) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-04-21. Analysts forecast an EPS of approximately $0.79-$0.80 forecasted. Medium importance is estimated as quarterly earnings are key drivers of stock valuation scheduled.
4/21/2026, 12:00:00 AM
Bank of Hawaii Corp (BOH) · Earnings Release
Q1 2026 earnings release is scheduled, with analysts forecasting an EPS of approximately $1.34 estimated.
4/20/2026, 12:00:00 AM